Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Friday, 2 June 2023, 11:20 HKT/SGT
Share:
    

Source: Eisai
Eisai to Present Latest Data on Lemborexant at the 37th Annual Sleep 2023 Meeting

TOKYO, June 2, 2023 - (JCN Newswire) - Eisai Co., Ltd. announced a total of eight poster presentations, including the latest data on its in-house discovered orexin receptor antagonist lemborexant (product name: DAYVIGO), will be given at the 37th annual meeting of the Associated Professional Sleep Societies (SLEEP 2023), to be held from June 3 to 7, 2023 in Indianapolis, IN, the United States.

Major poster presentations include new data about the effects of lemborexant on obstructive sleep apnea (poster numbers: #298, 299 and 300).

Eisai considers neurology, including insomnia, a therapeutic area of focus. Eisai strives to create innovative products as soon as possible in therapeutic areas with high unmet medical needs, and will further contribute to addressing the diverse needs of, as well as increasing the benefits provided to, those living with neurological diseases and their families.

About Lemborexant (product name: DAYVIGO)

Lemborexant, an orexin receptor antagonist, is Eisai's in-house discovered and developed small molecule that inhibits orexin neurotransmission by binding competitively to the two subtypes of orexin receptors (orexin receptor 1 and 2). Fast on/off receptor kinetics of lemborexant to orexin receptors may influence lemborexant's potential to facilitate improvements in sleep onset and maintenance with minimal morning residual effects. It has been approved for the treatment of insomnia in over 15 countries including Japan, the United States, Canada, Australia and countries in Asia.

For more information, visit www.eisai.com/news/2023/news202340.html.

Media Inquiries:

Public Relations Department
Eisai Co., Ltd.
+81-(0)3-3817-5120

Eisai Inc. (U.S.)
TEL: +551-305-0050
Christopher_Vancheri@eisai.com


Topic: Press release summary
Source: Eisai

Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
July 12, 2024 11:56 HKT/SGT
"LEQEMBI" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Israel
July 11, 2024 09:00 HKT/SGT
LEQEMBI (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Hong Kong
July 2, 2024 12:01 HKT/SGT
Eisai Announces Move to Solo Development and Commercialization of Farletuzumab Ecteribulin (FZEC) Antibody Drug Conjugate (ADC)
June 28, 2024 14:57 HKT/SGT
Eisai: "LEQEMBI" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in China
June 21, 2024 14:35 HKT/SGT
Eisai Continues Contract for FY2024 Dementia Examination Project by Tokyo Bunkyo City
June 10, 2024 17:50 HKT/SGT
FDA Accepts Eisai's Filing of LEQEMBI (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease
June 3, 2024 16:08 HKT/SGT
Eisai Named to List of The Time 100 Most Influential Companies
June 3, 2024 14:22 HKT/SGT
Eisai Strengthens Venture Investment Business Aimed at Accelerating Drug Discovery Innovation and Establishment of Ecosystem Platform
May 28, 2024 14:19 HKT/SGT
LEQEMBI (lecanemab) Approved for the Treatment of Alzheimer's Disease in South Korea
May 23, 2024 17:07 HKT/SGT
Eisai Showcases Oncology Portfolio and Pipeline at ASCO 2024
More news >>
 News Alerts
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: